Botulinum Toxin Enhanced Foker Process for Long Gap Esophageal Atresia.

Botox Botulinum toxin Esophagus Foker Long gap esophageal atresia Traction

Journal

Journal of pediatric surgery
ISSN: 1531-5037
Titre abrégé: J Pediatr Surg
Pays: United States
ID NLM: 0052631

Informations de publication

Date de publication:
16 Jul 2024
Historique:
received: 30 04 2024
revised: 30 06 2024
accepted: 11 07 2024
medline: 4 8 2024
pubmed: 4 8 2024
entrez: 3 8 2024
Statut: aheadofprint

Résumé

The traction-induced esophageal growth (Foker) process for the treatment of long gap esophageal atresia (LGEA) relies on applying progressive tension to the esophagus to induce growth. Due to its anti-fibrotic and muscle-relaxing properties, we hypothesize that Botulinum Toxin A (BTX) can enhance traction-induced esophageal growth. A retrospective two-center cohort study was conducted on children who underwent a BTX-enhanced Foker process for LGEA repair from 2021 to 2023. BTX (10 units/ml, 2 units/kg, per esophageal pouch) was applied at the time of traction initiation. Time on traction, complications, and anastomotic outcomes were compared against historical controls (Foker process without BTX) from 2014 to 2021. Twenty infants (LGEA type A:12, B:4, C:4; 35% reoperative; median [IQR] age 3 [2-5] months), underwent BTX-enhanced Foker process (thoracotomy with external traction: 9; minimally invasive [MIS] multi-staged internal traction: 11). Mean gap lengths were similar between BTX-enhanced external and external traction control patients (mean [SD], 50.6 mm [12.6] vs. 44.5 mm [11.9], p = 0.21). When compared to controls, the BTX-enhanced external traction process was significantly faster (mean [SD], 12.1 [1.6] days vs. 16.6 [13.2] without BTX, p = 0.04) despite similar preoperative gap lengths. There was no difference in time on traction for those undergoing a minimally invasive process. There were no significant differences in complications or anastomotic outcomes in either cohort. Botulinum toxin may play a role in accelerating the traction-induced esophageal growth process for LGEA repair. Minimizing time on traction can decrease sedation and paralysis burden while on external traction. Further studies are needed to elucidate the effects of BTX on the esophagus. Level III. Retrospective, Two-center, Cohort study.

Sections du résumé

BACKGROUND BACKGROUND
The traction-induced esophageal growth (Foker) process for the treatment of long gap esophageal atresia (LGEA) relies on applying progressive tension to the esophagus to induce growth. Due to its anti-fibrotic and muscle-relaxing properties, we hypothesize that Botulinum Toxin A (BTX) can enhance traction-induced esophageal growth.
METHODS METHODS
A retrospective two-center cohort study was conducted on children who underwent a BTX-enhanced Foker process for LGEA repair from 2021 to 2023. BTX (10 units/ml, 2 units/kg, per esophageal pouch) was applied at the time of traction initiation. Time on traction, complications, and anastomotic outcomes were compared against historical controls (Foker process without BTX) from 2014 to 2021.
RESULTS RESULTS
Twenty infants (LGEA type A:12, B:4, C:4; 35% reoperative; median [IQR] age 3 [2-5] months), underwent BTX-enhanced Foker process (thoracotomy with external traction: 9; minimally invasive [MIS] multi-staged internal traction: 11). Mean gap lengths were similar between BTX-enhanced external and external traction control patients (mean [SD], 50.6 mm [12.6] vs. 44.5 mm [11.9], p = 0.21). When compared to controls, the BTX-enhanced external traction process was significantly faster (mean [SD], 12.1 [1.6] days vs. 16.6 [13.2] without BTX, p = 0.04) despite similar preoperative gap lengths. There was no difference in time on traction for those undergoing a minimally invasive process. There were no significant differences in complications or anastomotic outcomes in either cohort.
CONCLUSION CONCLUSIONS
Botulinum toxin may play a role in accelerating the traction-induced esophageal growth process for LGEA repair. Minimizing time on traction can decrease sedation and paralysis burden while on external traction. Further studies are needed to elucidate the effects of BTX on the esophagus.
LEVEL OF EVIDENCE METHODS
Level III.
TYPE OF STUDY METHODS
Retrospective, Two-center, Cohort study.

Identifiants

pubmed: 39097496
pii: S0022-3468(24)00424-X
doi: 10.1016/j.jpedsurg.2024.07.013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors have no sources of financial support or conflicts of interest that are relevant to this work.

Auteurs

Shawn Izadi (S)

Department of Surgery, Boston Children's Hospital, Boston, MA, USA.

Donna C Koo (DC)

Department of Surgery, Boston Children's Hospital, Boston, MA, USA.

Hester F Shieh (HF)

Department of Surgery, Johns Hopkins All Children's Hospital, St Petersburg, FL, USA.

Megan Z Chiu (MZ)

Department of Surgery, Boston Children's Hospital, Boston, MA, USA.

Farokh R Demehri (FR)

Department of Surgery, Boston Children's Hospital, Boston, MA, USA.

Somala Mohammed (S)

Department of Surgery, Boston Children's Hospital, Boston, MA, USA.

Steven J Staffa (SJ)

Department of Surgery, Boston Children's Hospital, Boston, MA, USA.

Jason Smithers (J)

Department of Surgery, Johns Hopkins All Children's Hospital, St Petersburg, FL, USA.

Benjamin Zendejas (B)

Department of Surgery, Boston Children's Hospital, Boston, MA, USA. Electronic address: Benjamin.zendejas@childrens.harvard.edu.

Classifications MeSH